Treatment of Aggressive Pituitary Tumors with Immunotherapy

Individuals with tumors of the pituitary (adenomas and carcinomas) that grow in spite of treatment with radiation are eligible for our clinical trial investigating whether the two immunotherapies, nivolumab and ipilimumab, are able to shrink these tumors.  
The two immunotherapies, nivolumab and ipilimumab, are intravenous drugs that have revolutionized the treatment of melanoma and several other malignancies.  These drugs allow the immune system to recognize and attack tumor cells.  Individuals with pituitary tumors that grow in spite of standard treatments (in particular radiation) have few treatment options.   For that reason, we are performing this phase II trial evaluating the efficacy of this drug combination on eligible patients.  
For further information, please reach out to Andrew Lin, MD at 212-639-8392.  Additional information is on the ClinicalTrials.gov website (https://clinicaltrials.gov/ct2/show/NCT04042753).

Print